APA (7th ed.) Citation

B, P., S, H., DM, C., F, H., RA, B., L, G., . . . A, G. (2024). Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial. Gynecologic oncology, 184, 168. https://doi.org/10.1016/j.ygyno.2024.01.021

Chicago Style (17th ed.) Citation

B, Pothuri, et al. "Health-related Quality of Life in Patients with Newly Diagnosed Advanced Ovarian Cancer Treated with Niraparib Vs Placebo: Results from the Phase 3 Randomized PRIMA/ENGOT-OV26/GOG-3012 Trial." Gynecologic Oncology 184 (2024): 168. https://doi.org/10.1016/j.ygyno.2024.01.021.

MLA (9th ed.) Citation

B, Pothuri, et al. "Health-related Quality of Life in Patients with Newly Diagnosed Advanced Ovarian Cancer Treated with Niraparib Vs Placebo: Results from the Phase 3 Randomized PRIMA/ENGOT-OV26/GOG-3012 Trial." Gynecologic Oncology, vol. 184, 2024, p. 168, https://doi.org/10.1016/j.ygyno.2024.01.021.